| abstract |
【Task】 An object of the present invention is to provide a therapeutic agent for cancer that focuses on a different aspect from the conventional development of anticancer agents, that is, cell-cell adhesion of cancer cells. That is, an object of the present invention is to provide a therapeutic agent for cancer with reduced side effects, which suppresses proliferation of cancer cells and cell-cell adhesion of cancer cells. Another object of the present invention is to provide an antibody that recognizes the disintegrin domain of ADAM-15 and can be used as an anticancer agent. [Solution] An antibody that recognizes the disintegrin domain of ADAM-15 and that does not recognize the RGD sequence or loop region in the disintegrin domain of ADAM-15, such as an antibody that inhibits ADAM-15 and integrin αvβ3-dependent cell adhesion, such as ADAM- 15 and antibodies that inhibit integrin α9β1-dependent cell adhesion. [Selection figure] None |